March 27, 2014
1:00 pm to 2:00 pm EDT

Sponsored by

Symposium Course Description:

Learn how the world's largest viable tumor bank (144k specimens, 76 clinical diagnoses) is used to establish populations of PDXact™ Patient Derived Xenograft models, used throughout oncology R&D==from target discovery to development of clinical strategy.

An important aspect of PDXact™ models is that they are largely derived from prior-treated and metastatic patients, making them more approximate to the kinds of patients that drug developers recruit into late stage oncology clinical trials.

The breadth and depth of the tumor collection have enabled preclinical PDX-based population studies, helping to establish confident clinical development strategies== responsive patient populations, effective combination agents, predictive diagnostic tests, and strategies to delay resistance.

Learning Objective Bullet Points:

• Establishment & characterization of large-scale viable tumor banks
• Development & characterization of targeted PDX models
• Linking molecular and functional studies from patient derived models
• Benefits of population studies in preclinical setting
• Building confident clinical development strategies

Speaker Information

Thomas B. Broudy, Ph.D., CSO

Chief Scientific Officer
Molecular Response

Thomas Broudy, PhD, is Chief Scientific Officer at Molecular Response, responsible for scientific study design, technology evaluation, and establishment of validated service offerings in the company’s laboratory group.Prior to Molecular Response, Dr. Broudy served as Director at AltheaDx, working closely with the Business Development and R&D teams to establish successful genomic service offerings, including microarray, RT-PCR, and nucleic acid isolation. He led efforts that resulted in establishment of 6 partnership programs for biomarkers and companion diagnostic development in oncology and infectious disease with pharmaceutical and diagnostic companies.

Dr. Broudy spent six years at Affymetrix, an industry-leading manufacturer of microarray tools, where he helped grow the company’s pharmacogenomic and toxicogenomic solutions in support of pharmaceutical R&D. Specifically, Dr. Broudy led efforts to define requirements, content and applications for the company’s leading drug metabolizing enzyme and transporter genotyping microarray. He participated in multiple industry/academia collaborations, including studies with Marshfield Clinic to identify genetic markers for warfarin response, and represented the company in the PharmaADME working group.

Dr. Broudy earned his PhD in infectious disease from The Rockefeller University and studied host/microbial genomics in his postdoctoral research at The Rockefeller University Laboratory of Bacterial Pathogenesis and Immunology, as well as Stanford University School of Medicine.

Cost: No cost!